After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | Fier

[anonymous]

After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | FiercePharma


After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year

 

[anonymous]

$135 million from Eisai. That was your annual bonuses boys and girls!


“In fourth-quarter results released Tuesday, Biogen said Aduhelm generated just $1 million during the final three months of the year and $3 million for all of 2021. That pales in comparison to the $480 million Biogen reported in full-year selling, general and administrative (SG&A) expenses related to the drug. Of the SG&A total, Biogen's partner Eisai chipped in $135 million for U.S. expenses.”

 

[anonymous]

$135 million from Eisai. That was your annual bonuses boys and girls!


“In fourth-quarter results released Tuesday, Biogen said Aduhelm generated just $1 million during the final three months of the year and $3 million for all of 2021. That pales in comparison to the $480 million Biogen reported in full-year selling, general and administrative (SG&A) expenses related to the drug. Of the SG&A total, Biogen's partner Eisai chipped in $135 million for U.S. expenses.”

Eisai the dumpster fire of pharma

 

[anonymous]

Another brilliant business development deal from the so-called mind of Alex Scott. What an asshole.